Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing Minnesota as the study site, and removed the Minnesota Locations entry and the HHS Vulnerability Disclosure link. The page revision was updated to v3.3.3.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter revision indicator updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.1. There are no changes to study details or page content.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the government funding lapse notice about NIH operations and site status on this trial page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check54 days agoChange DetectedNo significant additions or deletions were detected; the page content and structure remain unchanged.SummaryDifference0.4%

- Check83 days agoChange DetectedUpgraded to version v3.2.0 with a funding-status notice about operational limitations; v3.1.0 was removed. Indicates a maintenance/availability update rather than new content.SummaryDifference4%

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.